Can 4-aminopyridine modulate dysfunctional gait networks in Parkinson's disease?

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Gait dysfunction and postural instability represent a major therapeutic challenge in Parkinson's disease (PD). Gait disability in PD has been historically attributed to striato-nigral degeneration, however there is emerging evidence that multiple neurotransmitter deficits contribute to mobility impairment in PD. 4-aminopyridine (4-AP), a potent neurotransmitter modulator, has a wide range of favorable effects on gait in patients with neurological conditions including multiple sclerosis, spinal cord injury and cerebellar ataxia. In this Review we identify the neurobiological pathways involved in gait dysfunction in PD and discuss the mechanisms of action of 4-AP and its effect on gait related neuronal networks. The proposed mechanisms that may facilitate 4-AP favorable effect on gait in Parkinson's disease include 1) neurotransmitter release (dopamine, glutamate, acetylcholine and noradrenaline) 2) modulation of neuronal network oscillations and 3) increased cortical excitation. Recent clinical trials of 4-AP in neurological conditions associated with gait disorders will be highlighted and the importance of studying non-dopaminergic medications such as 4-AP in PD patients with gait impairment will be emphasized.

Original languageEnglish
Pages (from-to)777-782
Number of pages6
JournalParkinsonism and Related Disorders
Volume19
Issue number9
DOIs
StatePublished - Sep 1 2013

Fingerprint

4-Aminopyridine
Gait
Parkinson Disease
Neurotransmitter Agents
Cerebellar Ataxia
Substantia Nigra
Spinal Cord Injuries
Acetylcholine
Multiple Sclerosis
Glutamic Acid
Dopamine
Norepinephrine
Clinical Trials

Keywords

  • 4-Aminopyridine
  • Basal ganglia
  • Gait dysfunction and postural instability
  • Neuronal networks
  • Non-dopaminergic treatment
  • Parkinson's disease

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Clinical Neurology
  • Neurology

Cite this

Can 4-aminopyridine modulate dysfunctional gait networks in Parkinson's disease? / Luca, Corneliu C; Singer, Carlos.

In: Parkinsonism and Related Disorders, Vol. 19, No. 9, 01.09.2013, p. 777-782.

Research output: Contribution to journalArticle

@article{8a18c306741a4bcc8b02bc9725d3de9f,
title = "Can 4-aminopyridine modulate dysfunctional gait networks in Parkinson's disease?",
abstract = "Gait dysfunction and postural instability represent a major therapeutic challenge in Parkinson's disease (PD). Gait disability in PD has been historically attributed to striato-nigral degeneration, however there is emerging evidence that multiple neurotransmitter deficits contribute to mobility impairment in PD. 4-aminopyridine (4-AP), a potent neurotransmitter modulator, has a wide range of favorable effects on gait in patients with neurological conditions including multiple sclerosis, spinal cord injury and cerebellar ataxia. In this Review we identify the neurobiological pathways involved in gait dysfunction in PD and discuss the mechanisms of action of 4-AP and its effect on gait related neuronal networks. The proposed mechanisms that may facilitate 4-AP favorable effect on gait in Parkinson's disease include 1) neurotransmitter release (dopamine, glutamate, acetylcholine and noradrenaline) 2) modulation of neuronal network oscillations and 3) increased cortical excitation. Recent clinical trials of 4-AP in neurological conditions associated with gait disorders will be highlighted and the importance of studying non-dopaminergic medications such as 4-AP in PD patients with gait impairment will be emphasized.",
keywords = "4-Aminopyridine, Basal ganglia, Gait dysfunction and postural instability, Neuronal networks, Non-dopaminergic treatment, Parkinson's disease",
author = "Luca, {Corneliu C} and Carlos Singer",
year = "2013",
month = "9",
day = "1",
doi = "10.1016/j.parkreldis.2013.04.024",
language = "English",
volume = "19",
pages = "777--782",
journal = "Parkinsonism and Related Disorders",
issn = "1353-8020",
publisher = "Elsevier BV",
number = "9",

}

TY - JOUR

T1 - Can 4-aminopyridine modulate dysfunctional gait networks in Parkinson's disease?

AU - Luca, Corneliu C

AU - Singer, Carlos

PY - 2013/9/1

Y1 - 2013/9/1

N2 - Gait dysfunction and postural instability represent a major therapeutic challenge in Parkinson's disease (PD). Gait disability in PD has been historically attributed to striato-nigral degeneration, however there is emerging evidence that multiple neurotransmitter deficits contribute to mobility impairment in PD. 4-aminopyridine (4-AP), a potent neurotransmitter modulator, has a wide range of favorable effects on gait in patients with neurological conditions including multiple sclerosis, spinal cord injury and cerebellar ataxia. In this Review we identify the neurobiological pathways involved in gait dysfunction in PD and discuss the mechanisms of action of 4-AP and its effect on gait related neuronal networks. The proposed mechanisms that may facilitate 4-AP favorable effect on gait in Parkinson's disease include 1) neurotransmitter release (dopamine, glutamate, acetylcholine and noradrenaline) 2) modulation of neuronal network oscillations and 3) increased cortical excitation. Recent clinical trials of 4-AP in neurological conditions associated with gait disorders will be highlighted and the importance of studying non-dopaminergic medications such as 4-AP in PD patients with gait impairment will be emphasized.

AB - Gait dysfunction and postural instability represent a major therapeutic challenge in Parkinson's disease (PD). Gait disability in PD has been historically attributed to striato-nigral degeneration, however there is emerging evidence that multiple neurotransmitter deficits contribute to mobility impairment in PD. 4-aminopyridine (4-AP), a potent neurotransmitter modulator, has a wide range of favorable effects on gait in patients with neurological conditions including multiple sclerosis, spinal cord injury and cerebellar ataxia. In this Review we identify the neurobiological pathways involved in gait dysfunction in PD and discuss the mechanisms of action of 4-AP and its effect on gait related neuronal networks. The proposed mechanisms that may facilitate 4-AP favorable effect on gait in Parkinson's disease include 1) neurotransmitter release (dopamine, glutamate, acetylcholine and noradrenaline) 2) modulation of neuronal network oscillations and 3) increased cortical excitation. Recent clinical trials of 4-AP in neurological conditions associated with gait disorders will be highlighted and the importance of studying non-dopaminergic medications such as 4-AP in PD patients with gait impairment will be emphasized.

KW - 4-Aminopyridine

KW - Basal ganglia

KW - Gait dysfunction and postural instability

KW - Neuronal networks

KW - Non-dopaminergic treatment

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=84880774627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880774627&partnerID=8YFLogxK

U2 - 10.1016/j.parkreldis.2013.04.024

DO - 10.1016/j.parkreldis.2013.04.024

M3 - Article

C2 - 23706539

AN - SCOPUS:84880774627

VL - 19

SP - 777

EP - 782

JO - Parkinsonism and Related Disorders

JF - Parkinsonism and Related Disorders

SN - 1353-8020

IS - 9

ER -